[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Zhang, Z.M., Lai, E.C., Zhang, C., et al. (2015) The Strategies for Treating Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. International Journal of Surgery, 20, 8-16. https://doi.org/10.1016/j.ijsu.2015.05.009
|
[3]
|
Cheng, A.L., Kang, Y.K., Chen, Z., et al. (2009) Efficacy and Safe-ty of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
|
[4]
|
程树群, 蔡建强, 陈敏山, 等. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版) [J]. 临床肝胆病杂志, 2019, 35(4): 737-743.
|
[5]
|
Hwang, S.Y., Kim, R.G., Choi, C.W., et al. (2016) Locoregional Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Liver Cancer, 16, 69-81. https://doi.org/10.17998/jlc.16.2.69
|
[6]
|
Kudo, M., Izumi, N., Ichida, T., et al. (2016) Report of the 19th Follow-Up Survey of Primary Liver Cancer in Japan: 19th Follow-Up Survey of Primary Liv-er Cancer in Japan. Hepatology Research, 46, 372-390.
https://doi.org/10.1111/hepr.12697
|
[7]
|
Cheng, S.Q., et al. (2007) Tumor Thrombus Types Influence the Progno-sis of Hepatocellular Carcinoma with the Tumor Thrombi in the Portal Vein. Hepatogastroenterology, 54, 499-502.
|
[8]
|
Sun, J.J., Wang, K., Zhang, C.Z., et al. (2016) Postoperative Adjuvant Transcatheter Arterial Chemoem-bolization after R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion. Annals of Surgical Oncology, 23, 1344-1351. https://doi.org/10.1245/s10434-015-5008-z
|
[9]
|
Luo, J., Guo, R.P., Lai, E., et al. (2011) Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. Annals of Surgical Oncology, 18, 413-420.
https://doi.org/10.1245/s10434-010-1321-8
|
[10]
|
Xiang, X., Lau, W.Y., Wu, Z.Y., et al. (2019) Transarterial Che-moembolization versus Best Supportive Care for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Study. European Journal of Surgical Oncology, 45, 1460-1467. https://doi.org/10.1016/j.ejso.2019.03.042
|
[11]
|
Lo, C.M., Ngan, H., Tso, W.K., et al. (2002) Randomized Con-trolled Trial of Transarterial Lipiodol Chemoembolization for Unresectable Hepatocellular Carcinoma. Hepatology, 35, 1164-1171. https://doi.org/10.1053/jhep.2002.33156
|
[12]
|
Llovet, J.M., Real, M.I., Montaña, X., et al. (2002) Arte-rial Embolisation or Chemoembolisation versus Symptomatic Treatment in Patients with Unresectable Hepatocellular Carcinoma: A Randomised Controlled Trial. The Lancet, 359, 1734-1739. https://doi.org/10.1016/S0140-6736(02)08649-X
|
[13]
|
Song, M.J. (2015) Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. World Journal of Gastroenterology, 21, 3843-3849. https://doi.org/10.3748/wjg.v21.i13.3843
|
[14]
|
Choi, J.H., Chung, W.J., Bae, S.H., et al. (2018) Randomized, Pro-spective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Pa-tients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Phar-macology, 82, 469-478.
https://doi.org/10.1007/s00280-018-3638-0
|
[15]
|
Zhang, W., Ouyang, D., Huang, Z., et al. (2023) Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: An Updated Meta-Analysis and Systematic Review. Frontiers in Oncology, 13, Article ID: 1085166. https://doi.org/10.3389/fonc.2023.1085166
|
[16]
|
Yin, J., et al. (2017) New Evidence and Perspectives on the Man-agement of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Clinical and Translational Hepa-tology, 5, 169-176.
http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=1&id=10.14218%2fJCTH.2016.00071
|
[17]
|
Rim, C.H., Yang, D.S., Park, Y.J., et al. (2012) Effectiveness of High-Dose Three-Dimensional Conformal Radiotherapy in Hepatocellular Carcinoma with Portal Vein Thrombosis. Japanese Journal of Clinical Oncology, 42, 721-729.
https://doi.org/10.1093/jjco/hys082
|
[18]
|
Xi, M., Zhang, L., Zhao, L., et al. (2013) Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis. PLOS ONE, 8, e63864.
https://doi.org/10.1371/journal.pone.0063864
|
[19]
|
Park, H.C., Yu, J.I., Cheng, J.C.H., et al. (2016) Consensus for Radiotherapy in Hepatocellular Carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer, 5, 162-174. https://doi.org/10.1159/000367766
|
[20]
|
Oladeru, O.T., Miccio, J.A., Yang, J., et al. (2016) Conformal External Beam Radiation or Selective Internal Radiation Therapy—A Comparison of Treatment Outcomes for Hepatocellular Car-cinoma. Journal of Gastrointestinal Oncology, 7, 433-440. https://doi.org/10.21037/jgo.2015.10.04
|
[21]
|
Llovet, J.M., Hilgard, P., De Oliveira, A.C., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
|
[22]
|
Bruix, J., Raoul, J.L., Sherman, M., et al. (2012) Efficacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Subanalyses of a Phase III Trial. Journal of Hepatology, 57, 821-829.
https://doi.org/10.1016/j.jhep.2012.06.014
|
[23]
|
Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcino-ma. The Lancet, 391, 1301-1314.
https://doi.org/10.1016/S0140-6736(18)30010-2
|
[24]
|
Hilgard, P., Hamami, M., Fouly, A.E., et al. (2010) Radio-embolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term Survival. Hepatology, 52, 1741-1749.
https://doi.org/10.1002/hep.23944
|
[25]
|
Lee, V., Leung, D., Luk, M.Y., et al. (2015) Yttrium-90 Radioembolization for Advanced Inoperable Hepatocellular Carcinoma. OncoTargets and Therapy, 8, 3457-3464. https://doi.org/10.2147/OTT.S92473
|
[26]
|
Liao, Y.Y., Zhong, J.H., Peng, N.F., et al. (2016) Is Radioembolization or Sorafenib the Best Option for Patients with Hepatocellular Carcinoma and Portal Vein Invasion? Liver International, 36, 1715-1715.
https://doi.org/10.1111/liv.13208
|
[27]
|
Pan, T., Li, X.S., Xie, Q.K., et al. (2014) Safety and Efficacy of Transarterial Chemoembolization plus Sorafenib for Hepatocellular Carcinoma with Portal Venous Tumour Thrombus. Clinical Radi-ology, 69, e553-e561.
https://doi.org/10.1016/j.crad.2014.09.007
|
[28]
|
Zhang, X., Wang, K., Wang, M., et al. (2017) Transarterial Che-moembolization (TACE) Combined with Sorafenib versus TACE for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Oncotarget, 8, 29416-29427. https://doi.org/10.18632/oncotarget.15075
|
[29]
|
Long, J., et al. (2016) Microwave Ablation of Hepatocellular Car-cinoma with Portal Vein Tumor Thrombosis after Transarterial Chemoembolization: A Prospective Study. Hepatology International, 10, 175-184.
https://doi.org/10.1007/s12072-015-9673-6
|
[30]
|
Kimura, T., Kato, Y., Ozawa, Y., et al. (2018) Immunomodulatory Activity of Lenvatinib Contributes to Antitumor Activity in the Hepa1‐6 Hepatocellular Carcinoma Model. Cancer Sci-ence, 109, 3993-4002.
https://doi.org/10.1111/cas.13806
|
[31]
|
Nakamoto, N., Cho, H., Shaked, A., et al. (2009) Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade. PLoS Pathogens, 5, e1000313.
https://doi.org/10.1371/journal.ppat.1000313
|
[32]
|
Duffy, A.G., Ulahannan, S.V., Makorova-Rusher, O., et al. (2017) Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatology, 66, 545-551.
https://doi.org/10.1016/j.jhep.2016.10.029
|